Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 8, keine Gesamtzahl für „When“
Suchtreffer
Begriffe & Kennungen
Briviact (in Italy: Nubriveo) · 4.8 · No specific pattern of adverse event (AE) was identified in children from 1◦month to < 4◦years of age when com
Eintrag öffnenBriviact (in Italy: Nubriveo) · 4.8 · No specific pattern of adverse event (AE) was identified in children from 1◦month to < 4◦years of age when com
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBrukinsa · 4.5 · No clinically significant differences in zanubrutinib pharmacokinetics were observed when co-administered with
Eintrag öffnenBuccolam · 4.8 · The table below lists the adverse reactions reported to occur when oromucosal midazolam was administered in cl
Eintrag öffnenBuvidal · 4.5 · 8 expected to have less effects on buprenorphine metabolism when co-administered with Buvidal as compared to w
Eintrag öffnenBuvidal · 4.5 · Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioi
Eintrag öffnenBuvidal · 4.5 · Buprenorphine should be used cautiously when co-administered with: • naltrexone and nalmefene: These are opioi
Eintrag öffnenBysumlog · 4.5 · The physician should be consulted when using other medications in addition to Bysumlog (see section 4.4).
Eintrag öffnenCabometyx · 4.8 · Cabozantinib in combination with nivolumab in first-line advanced RCC Summary of safety profile When cabozanti
Eintrag öffnenCabometyx · 4.8 · Elevated liver enzymes when cabozantinib is combined with nivolumab in RCC In a clinical study of previously u
Eintrag öffnenCabometyx · 4.8 · Physeal widening has been observed in children with open growth plates when treated with cabozantinib.
Eintrag öffnenCalquence · 4.5 · No clinically significant differences in acalabrutinib pharmacokinetics were observed when a 100 mg acalabruti
Eintrag öffnenCalquence · 4.8 · Serious infections when treating patients with Calquence in combination with venetoclax with or without obinut
Eintrag öffnenCalquence · 4.8 · Serious infections when treating patients with Calquence in combination with venetoclax with or without obinut
Eintrag öffnenCapecitabine Accord · 4.5 · Interferon alpha The MTD of capecitabine was 2000 mg/m2 per day when combined with interferon alpha-2a (3 MIU/
Eintrag öffnenCapecitabine Medac · 4.5 · Interferon alpha The MTD of capecitabine was 2,000 mg/m² per day when combined with interferon alpha- 2a (3 MI
Eintrag öffnenCapecitabine Teva · 4.5 · Interferon alpha The MTD of capecitabine was 2000 mg/m2 per day when combined with interferon alpha- 2a (3 MIU
Eintrag öffnenCapecitabine Teva · 4.5 · Radiotherapy The MTD of capecitabine alone using the intermittent regimen is 3000 mg/m2 per day, whereas, when
Eintrag öffnenCellCept · 4.5 · 49 4.4). Conversely, changes of MPA exposure should be expected when switching patients from CsA to one of the
Eintrag öffnen